CONTINGENT PAYMENT (Details Narrative) |
9 Months Ended |
|---|---|
|
Sep. 30, 2026
USD ($)
| |
| CONTINGENT PAYMENT | |
| Net sales and profit sharing | $ 400,000 |
| Upfront purchase price | $ 400,000 |
| Seller for purchase of assets description | the Net Sales (as defined in the APA) of LUCEMYRA® and 50% of the Net Distributable Profits (as defined in the APA) of the generic version of LUCEMYRA®. The Company shall also pay to the Seller a royalty equal to 3% of the Net Sales of LUCEMYRA® and 3% of the Net Distributable Profits |
| Royalty payments period | 5 years |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|